G Bradley Cole Sells 3,673 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director G Bradley Cole sold 3,673 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director owned 11,672 shares in the company, valued at approximately $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $74.34 on Friday. The stock has a 50-day simple moving average of $59.04 and a 200-day simple moving average of $51.13. The stock has a market cap of $5.72 billion, a P/E ratio of 76.64 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1 year low of $29.90 and a 1 year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.38 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Handelsbanken Fonder AB purchased a new position in shares of Kiniksa Pharmaceuticals International during the second quarter worth approximately $1,343,000. Financial Enhancement Group LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $2,007,000. Bank of America Corp DE raised its position in Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Kiniksa Pharmaceuticals International by 213.5% during the 1st quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after purchasing an additional 327,595 shares during the period. Finally, California State Teachers Retirement System boosted its stake in Kiniksa Pharmaceuticals International by 33.3% during the 1st quarter. California State Teachers Retirement System now owns 41,975 shares of the company’s stock worth $2,021,000 after purchasing an additional 10,477 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Kiniksa reported second-quarter revenue of $243.6 million, ahead of the $226.5 million consensus estimate, while adjusted earnings of $0.30 per share matched expectations. The results support continued commercial momentum and helped underpin the recent analyst optimism. Kiniksa Pharmaceuticals International 2026 Q2 Results Earnings Call Presentation
• Positive Sentiment: Several firms raised or reiterated bullish views. Goldman Sachs set a $90 price target, JPMorgan raised its target to $107, and Canaccord Genuity and Citigroup forecast additional appreciation. The broader analyst consensus remains “Buy,” with an average target of $87.38. Goldman Sachs Kiniksa Price Target JPMorgan Kiniksa Price Target
• Neutral Sentiment: Institutional ownership remains substantial at approximately 54%, with several funds increasing their positions. This may provide shareholder support, although the transactions cited largely reflect prior-quarter activity rather than a new catalyst.
• Negative Sentiment: Zacks Research downgraded KNSA from “Strong Buy” to “Hold.” The change may be contributing to profit-taking concerns after the stock’s sharp advance and elevated valuation.
• Negative Sentiment: Director G. Bradley Cole sold 3,673 shares at an average price of $81.43, reducing his position by 23.94%. While one insider sale does not establish a trend, it can weigh on sentiment, particularly near the stock’s recent high. G Bradley Cole Sells Kiniksa Shares

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Finally, Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average target price of $87.38.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.